- EyeTech Pharmaceuticals gets rights to Gilead's NX 1838
- EyeTech closes $108.5mm Series C placement
- Pfizer develops Eyetech's Macugen
- Neurocrine licenses sleep drug from DOV
- Pfizer, Neurocrine end agreement for indiplon
- Pfizer co-promotes Serono's Rebif in the US
- Pfizer acquires Pharmacia in $59bn all stock deal
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. firstname.lastname@example.org.
All fields are required.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.